Botulinum Toxin Treatment Policy
Criteria Based Access (CBA)
If the patient demonstrably meets the specific criteria for treatment, the patient can be referred directly via the appropriate Referral Service with a standard referral letter. If the patient does not meet the criteria for treatment then a referral can be made to the Individual Funding Request Panel but only if there is clear evidence that the patient’s clinical circumstances or condition are exceptional, i.e. there is something about the patient’s condition or circumstances that differentiate them on the basis of need from other patients with a similar diagnosis or condition and would justify funding being provided in an individual case when it is not routinely funded for others. Funding requests from GP Practices can be accepted from Senior Clinicians, salaried GPs, Locum GPs or Practice Partners. Unfortunately we are unable to accept funding applications from other health professionals unless countersigned by a senior clinician or GP.
If you would like this policy in a different language or need it in another format, such as Braille, please contact the Patient Advice and Liaison Service on 0800 073 0907 or 0117 947 4477.
Botulinum toxin is a neurotoxicprotein produced by the bacteriumclostridium botulinum and related species. It is also produced commercially for medical, cosmetic, and research use. There are two main commercial types: botulinum toxin type A and botulinum toxin type B. Botulinum toxin types A and B are used in medicine for, among others, upper motor neuron syndrome, focal hyperhidrosis, blepharospasm, strabismus, chronic migraine and bruxism. It is also widely used in cosmetic treatments. There is a number of botulinum toxin type A products commercially available including Botox ® , Dysport ® , Xeomin ® ). Other brands are available but are only licensed for cosmetic procedures. (Allergan).
Botulinum Toxin treatment is only routinely funded for specific indications as outlined on the BNSSG JFG website ; botulinum toxin for any other indication is not routinely funded by the CCG.